PharmaShots Weekly Snapshots (November 06–10, 2023)

Share this

PharmaShots Weekly Snapshots (November 06–10, 2023)

This week PharmaShots’ news was all about the updates on clinical trials, regulatory,   pharma, Animal Health and DigiHealth. Check out our full report below:

BioCryst Pharmaceuticals and Clearside Biomedical Sign a Licence Agreement for the Development of Avoralstat Treating Patients with Diabetic Macular Edoema

Read More: BioCryst Pharmaceuticals & Clearside Biomedical

Atara Biotherapeutics and Laboratoires Pierre Fabre Expand Their Collaboration Agreement to Continue Developing and Marketing Ebvallo Worldwide

Read More: Atara Biotherapeutics & Laboratoires Pierre Fabre

Biotheus Enters into a Collaboration Agreement with BioNTech to Develop and Commercialize PM8002 for the Treatment of Multiple Solid Tumor Indications

Read More: Biotheus & BioNTech                                                                          

Jazz Pharmaceuticals and MD Anderson Cancer Centre Sign a 5-Year Research Collaboration Agreement to Investigate Zanidatamab in Solid Tumours

Read More: Jazz Pharmaceuticals                                                                   

Dewpoint Therapeutics and Evotec Enter into a Strategic Partnership to Accelerate Dewpoint's Oncology Pipeline

Read More: Dewpoint Therapeutics & Evotec                                             

Veracyte has Entered into a Multi-Year Partnership with Illumina to Improve its in vitro Diagnostic (IVD) Tests and Expand Global Access for Patients

Read More: Veracyte & Illumina                                                                            

Eccogene and AstraZeneca Signed a Collaboration Agreement to Develop and Commercialize ECC5004 for Cardiometabolic Diseases

Read More: Eccogene & AstraZeneca                                                                

Century Therapeutics Enters into a Collaboration Agreement with FUJIFILM Cellular Dynamics to Develop and Commercialize iPSC-Derived Cell Therapies for Autoimmune and Inflammatory Diseases

Read More: Century Therapeutics & FUJIFILM Cellular Dynamics                

The US FDA Designated Plus Therapeutics' Rhenium (186Re) Obisbemeda as an Orphan Drug to Treat Breast Cancer with Leptomeningeal Metastases

Read More: Plus Therapeutics                                                                                 

The US FDA Approves Cabaletta's IND Application for CABA-201 to Treat Generalised Myasthenia Gravis (gMG)

Read More: Cabaletta                                                                                             

Samsung Bioepis & Organon's sBLA for Hadlima (Biosimilar, adalimumab) to Treat Plaque Psoriasis was Approved for Review by the US FDA                                                             

Read More: Samsung Bioepis & Organon's sBLA                                               

Recor Medical and Otsuka Medical Devices’ Paradise Ultrasound Renal Denervation System for Hypertension Received the US FDA’s Approval

Read More: Recor Medical & Otsuka Medical Devices                                   

The US FDA has Approved Takeda's Fruzaqla to Treat Metastatic Colorectal Cancer

Read More: Takeda                                                                                         

The US FDA Approved Eli Lilly’s Zepbound (tirzepatide) as a Treatment for Obesity or Overweight

Read More: Eli Lilly                                                                                               

BMS Reports that the sBLA for Breyanzi (lisocabtagene maraleucel) was Accepted by the US FDA's for the Treatment of Small Lymphocytic Lymphoma (SLL) and Chronic Lymphocytic Leukaemia (CLL) with a Priority Review

Read More: BMS                                                                                                     

The US FDA Designates Lyell Immunopharma's LYL845 as an Orphan Drug to Treat Melanoma

Read More: LyellImmunopharma                                                                          

MaaT Pharma Reports on the First MaaT033 Patient Dosage in the P-IIb Trial for Patients with Blood Cancer

Read More: MaaT Pharma                                                                                    

TILT Biotherapeutics Reports Results of the P-I Trial Evaluating TILT-123 for the Treatment of Solid Tumors SITC 2023

Read More: TILT Biotherapeutics                                                                          

Results for Eblasakimab in Atopic Dermatitis and Chronic Obstructive Pulmonary Disease (COPD) were Presented by ASLAN Pharmaceutical at the DDDS 2023

Read More: ASLAN Pharmaceutical                                                                   

Results from Two Studies for 124I-Evuzamitide by Attralus were Published in the Journal of the American College of Cardiology

Read More: Attralus                                                                                              

Travere Therapeutics, Filspari, IgA Nephropathy, IgAN, Focal Segmental Glomerulosclerosis, FSGS, Clinical Trials, P-III, PROTECT, DUPLEX

Read More: Travere Therapeutics                                                                       

Results of Portable Neuromodulation Stimulator (PoNS) Therapy for Patients with Traumatic Brain Injury (TBI) were Reported by Helius Medical Technologies

Read More: Helius Medical Technologies                                                        

Atara Biotherapeutics Reports Results from the P-II Trial Evaluating ATA188 in Patients with Non-Active Progressive Multiple Sclerosis

Read More: Atara Biotherapeutics                                                                     

Amgen Presents Results from the P-IV (FOREMOST) Trial Investigating Otezla (apremilast) for Early Oligoarticular Psoriatic Arthritis

Read More: Amgen                                                                                               

Abbott Reports Diabetes Treatment Outcomes from a Real-World Study Evaluating its Healthy Food Rx Program

Read More: Abbott                                                                                           

AstraZeneca Highlights Imfinzi's P-III Trial Results for the Treatment of Hepatocellular Carcinoma

Read More: AstraZeneca                                                                              

Ionis Pharmaceuticals Highlight Results of the P-II Trial for Donidalorsen as a Treatment for Type 1 and Type 2 Hereditary Angioedema

Read More: Ionis Pharmaceuticals                                                                   

Antech Launches a New UK-Based Veterinary Diagnostics Facility

Read More: Antech                                                                                              

 GE HealthCare Signs a Collaboration Agreement with Masimo to Combine Masimo SET Pulse Oximetry with the Portrait Mobile Platform

Read More: GE HealthCare & Masimo                                                           

Mainz Biomed Enters into a Collaboration Agreement with Liquid Biosciences to Develop AI Enables Screening Tests for Colorectal Cancer

Read More: Mainz Biomed & Liquid Biosciences                                          


Related Post: PharmaShots Weekly Snapshots (October 30– November 03, 2023)


Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions